Cardiac Resynchronization Therapy Is More Effective in Women Than in Men: The MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy) Trial

详细信息    查看全文

• 作者：Aysha Arshad MD ; Arthur J. Moss MD^† ; ; ^{heartajm@heart.rochester.edu} ; Elyse Foster MD^‡ ; ; Luigi Padeletti MD^§ ; ; Alon Barsheshet MD^† ; ; Ilan Goldenberg MD^† ; ; Henry Greenberg MD ; W. Jackson Hall PhD^† ; ; Scott McNitt MS^† ; ; Wojciech Zareba MD ; PhD^† ; ; Scott Solomon MD ; Jonathan S. Steinberg MD ; MADIT-CRT Executive Committee
• 关键词：cardiac resynchronization therapy ; MADIT-CRT ; women
• 刊名：Journal of the American College of Cardiology
• 出版年：2011
• 出版时间：15 February 2011
• 年：2011
• 卷：57
• 期：7
• 页码：813-820
• 全文大小：624 K

文摘

Objectives

The purpose of this study was to investigate the factors related to sex-specific outcomes for death and heart failure events in the MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy) trial.

Background

In the MADIT-CRT trial, women seemed to achieve a better result from resynchronization therapy than men.

Methods

All 1,820 patients (453 female and 1,367 male) enrolled in the MADIT-CRT trial were included in this sex-specific outcome analysis that compared the effect of cardiac resynchronization therapy with defibrillator (CRT-D) relative to implanted cardioverter-defibrillator (ICD) on death or heart failure (whichever came first), heart failure only, and death at any time.

Results

Female patients were more likely to have nonischemic cardiomyopathy and left bundle branch block and less likely to have renal dysfunction than male patients. Overall, female patients had a better result from CRT-D therapy than male patients, with a significant 69 % reduction in death or heart failure (hazard ratio: 0.31, p < 0.001) and 70 % reduction in heart failure alone (hazard ratio: 0.30, p < 0.001). Women had a significant 72 % reduction in all-cause mortality in the total population (hazard ratio: 0.28, p = 0.02) and significant 82 % and 78 % reductions in mortality in those with QRS ≥150 ms and with left bundle branch block conduction disturbance, respectively, with sex-by-treatment interactions for mortality reduction significant at p < 0.05 in each of these 3 patient groups. These beneficial CRT-D effects among women were associated with consistently greater echocardiographic evidence of reverse cardiac remodeling in women than in men.

Conclusions

Women in the MADIT-CRT trial obtained significantly greater reductions in death or heart failure (whichever came first), heart failure alone, and all-cause mortality with CRT-D therapy than men, with consistently greater echocardiographic evidence of reverse cardiac remodeling in women than in men. (Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy [MADIT-CRT]; NCT00180271).